[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:rad51b-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"RAD51B Gene",8,4,[8,16,23,29,35,42,49,55],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05687110","Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes",[12],"Phase 1","RECRUITING","2026-08-26T02:17:58.890423Z","2026-05-05T02:43:27.808389Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT03786796","Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations",[20],"Phase 2","2026-08-26T02:18:38.077159Z","2026-05-05T02:35:31.766251Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06458712","Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies",[12],"2026-08-26T02:15:51.395565Z","2026-07-24T01:27:14.872137Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT04038502","Carboplatin or Olaparib for BRcA Deficient Prostate Cancer",[20],"2026-08-26T02:18:40.612983Z","2026-05-05T02:43:29.505079Z",{"nct_id":36,"title":37,"phases":38,"status":39,"updated_at":40,"content_modified":41},"NCT07723651","[18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)",[20],"NOT_YET_RECRUITING","2026-08-26T02:19:11.399072Z","2026-07-24T01:27:14.924205Z",{"nct_id":43,"title":44,"phases":45,"status":46,"updated_at":47,"content_modified":48},"NCT06212583","High-Risk Metachronous Oligometastatic Prostate Cancer Trial",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T02:25:31.771325Z","2026-05-05T02:43:29.167176Z",{"nct_id":50,"title":51,"phases":52,"status":46,"updated_at":53,"content_modified":54},"NCT05498272","Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations",[20],"2026-08-03T02:05:27.322885Z","2026-05-05T02:43:27.674415Z",{"nct_id":56,"title":57,"phases":58,"status":46,"updated_at":59,"content_modified":60},"NCT04550494","Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations",[20],"2026-08-03T03:54:23.387833Z","2026-05-05T02:43:29.385344Z"]